Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Capital Expenditures (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Capital Expenditures for 7 consecutive years, with $33000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 105.44% to $33000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 293.19% year-over-year, with the annual reading at $1.1 million for FY2025, 293.19% up from the prior year.
  • Capital Expenditures hit $33000.0 in Q4 2025 for BridgeBio Pharma, down from $1.1 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $9.4 million in Q3 2021 to a low of -$10.1 million in Q4 2021.
  • Historically, Capital Expenditures has averaged $474470.6 across 5 years, with a median of $96000.0 in 2023.
  • Biggest YoY gain for Capital Expenditures was 1609.84% in 2021; the steepest drop was 572.83% in 2021.
  • Year by year, Capital Expenditures stood at -$10.1 million in 2021, then soared by 146.92% to $4.8 million in 2022, then crashed by 76.6% to $1.1 million in 2023, then crashed by 154.49% to -$607000.0 in 2024, then soared by 105.44% to $33000.0 in 2025.
  • Business Quant data shows Capital Expenditures for BBIO at $33000.0 in Q4 2025, $1.1 million in Q3 2025, and -$607000.0 in Q4 2024.